Given that LAG3 is expressed in active CD4 + and CD8 + T cells, we can view its elevation as an outward manifestation of the presence of more effector lymphocytes in the tumor tissues, whereas more lymphocytes equate to more active tumor immunity and more benefits for ESCC patients[3, 12]. This evidence concerns the gene CD8A and neoplasm.